Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

NCT ID: NCT00284154


Title
A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
Purpose
This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.
Details
Eligible patients will receive vinflunine as a 15-20 minute intravenous (IV)infusion once every three weeks (21 days). This three week treatment period is called a cycle. Patients whose cancer has not grown or if it has decreased in size may receive up to 6 cycles of vinflunine. Evaluation will be conducted every other cycle.
Conditions
Carcinoma, Small Cell, Lung Cancer
Keywords
Extensive stage, Relapsed
Source
SCRI Development Innovations, LLC
Sponsors
SCRI Development Innovations, LLC, Bristol-Myers Squibb
Status
Completed
Acronym
Last Updated
07 Feb 2013
URL
Official Link
Citations/Publications
Spigel DR, Hainsworth JD, Lane CM, Clark B, Burris HA, Greco FA. Phase II trial of vinflunine in relapsed small cell lung cancer. J Thorac Oncol. 2010 Jun;5(6):874-8.

Locations
United States